Humanized Anti-EphA4 Antibody for Neurodegenerative Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and spinal cord injury lack effective inhibitors that specifically target EphA4, a receptor tyrosine kinase involved in axonal guidance, to inhibit its binding with ephrin ligands.
Innovation Solution
Development of a humanized anti-EphA4 antibody or its fragment that binds to EphA4, specifically inhibiting the interaction with ephrin ligands, comprising specific CDR sequences and derived from human IgG and Igκ regions, with various forms including Fab, F(ab')2, and Fv formats.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EphA4 signaling inhibitors (KYL peptide, compound 1) are used, then EphA4 binding is inhibited, but therapeutic effectiveness is insufficient for neurodegenerative diseases
Solution Approach 1:
The patent changes the molecular parameters of the inhibitor by transitioning from small molecule peptides (KYL peptide, compound 1) to a full-length monoclonal antibody (anti-EphA4 antibody). This parameter change increases the molecular weight, complexity, and binding affinity, resulting in superior therapeutic effectiveness for neurodegenerative diseases while maintaining the core function of EphA4 inhibition.
2Reliability
If non-specific EphA4 inhibitors are used, then binding inhibition occurs, but specificity to EphA4-ephrin interaction is insufficient
Solution Approach 1:
The patent applies local quality by designing the anti-EphA4 antibody to target a specific epitope on the EphA4 receptor. The antibody's complementarity-determining regions (CDRs) are engineered to recognize and bind with high specificity to a particular local region of EphA4, ensuring that inhibition is focused on the EphA4-ephrin interaction without affecting other Eph receptors or signaling pathways.
3Reliability
If antibody therapy is developed, then neutralizing activity is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent uses phage display technology as an intermediary method to simplify antibody development. By displaying antibody fragments on phage surfaces and selecting them through binding to EphA4, the technology provides a systematic approach to identify and isolate high-affinity anti-EphA4 antibodies, reducing the overall complexity of antibody therapy development and manufacturing.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.